Peptic Ulcer Drugs Market
Number of pages: 100 | Report Format: PDF | Published date: October 13, 2022
Historical Years – 2023 | Base Year – 2023 | Forecasted Years – 2024-2032
|
Report Attribute |
Details |
|
Market size value in 2023 |
US$ 467.38 million |
|
Revenue forecast in 2032 |
US$ 816.01 million |
|
Growth Rate |
CAGR of 6.34% from 2024 to 2032 |
|
Base year for estimation |
2023 |
|
Forecast period |
2024-2032 |
|
Segments covered |
Drug type, ulcer type, distribution channel, and region. |
|
Regional scope |
North America, Europe, Asia Pacific, and the Rest of the World (ROW) |
According to the deep-dive market assessment study by Growth Plus Reports, the global peptic ulcer drugs market was valued at US$ 467.38 million in 2023 and is expected to register a revenue CAGR of 6.34% to reach US$ 816.01 million by 2032.
Peptic Ulcer Drugs Market Fundamentals
Peptic ulcers are open sores that develop on the inner lining of the stomach, upper small intestine, or esophagus, commonly caused by Helicobacter pylori (H.pylori) bacteria or prolonged use of nonsteroidal anti-inflammatory drugs (NSAIDs). To manage and treat peptic ulcers, various medications are employed. Proton pump inhibitors (PPIs) such as omeprazole and H2 blockers like ranitidine are commonly prescribed. These drugs work by reducing the production of stomach acid, helping to promote the healing of the ulcer. Additionally, antibiotics may be prescribed if H. pylori infection is identified as a contributing factor. Antacids, providing quick relief by neutralizing stomach acid, are also used for symptomatic relief. Treatment plans are often tailored based on the underlying cause of the peptic ulcer, aiming to alleviate symptoms, promote healing, and prevent recurrence.
Peptic Ulcer Drugs Market Dynamics
The prevalence of peptic ulcers, attributed to factors like Helicobacter pylori infection and the widespread use of nonsteroidal anti-inflammatory drugs (NSAIDs), is a primary driver of demand for effective medications. The increasing geriatric population, more susceptible to peptic ulcers, adds to the demographic requiring medical intervention. Lifestyle factors, including stress and unhealthy dietary habits, contribute to the demand for pharmaceutical solutions. The rising incidence of H. pylori infection, a significant cause of peptic ulcers, further fuels the need for drugs targeting this bacterial factor. Advancements in drug development and formulations, along with improved awareness and diagnostics, enhance early detection and treatment. Access to healthcare services, particularly in emerging markets, facilitates diagnosing and managing peptic ulcers. Patient compliance is encouraged by the development of drugs with convenient dosing regimens and fewer side effects. Additionally, strategic collaborations and partnerships within the pharmaceutical industry drive innovation and the introduction of new therapeutic options, further fostering growth in the global peptic ulcer drugs market.
However, generic competition, side effects, and the emergence of alternative therapies pose challenges to the global peptic ulcer drugs market. The availability of generic versions creates pricing pressures, limiting revenue for pharmaceutical companies. Safety concerns associated with some medications may impact patient adherence and cause hesitancy among healthcare providers. The rise of alternative therapies, including lifestyle modifications and natural remedies, may divert patients from traditional pharmaceutical treatments. High development costs hinder investments in novel therapeutic options, limiting innovation. The increasing preference for minimally invasive procedures, such as endoscopic therapies, offers alternatives to drug-based treatments. Antibiotic resistance, regulatory challenges, and limited awareness and diagnosis further impact the market. The COVID-19 pandemic has disrupted healthcare priorities, diverting attention from peptic ulcer management and leading to a temporary decline. Patient non-adherence due to complex regimens and side effect concerns affects the effectiveness of drug-based therapies and overall market growth.
Market Ecosystem
The global peptic ulcer drugs market is analyzed from the following perspectives: by drug class, type, distribution channel, and region.
Peptic Ulcer Drugs Market by Drug Class
Based on drug class, the global peptic ulcer drugs market is segmented into antibiotics, H2 antagonist inhibitors, proton pump inhibitors, and others.
Several factors are responsible for the dominance of the antibiotics segment in the global market. Foremost among these is the etiological role of H. pylori infection in peptic ulcers, necessitating antibiotics for precise targeting and eradication of the bacterial causative agent. Antibiotics are frequently integrated into combination therapies, synergizing with other medications to establish a comprehensive approach to managing peptic ulcers. The elevated success rates in H. pylori eradication significantly contribute to efficient ulcer healing and a diminished risk of recurrence, thus reinforcing the extensive utilization of antibiotics. The endorsement of antibiotic use in global medical guidelines and recommendations exerts influence on clinical practices, further consolidating their dominance. Antibiotics provide a focused therapeutic strategy, mitigating collateral damage and averting complications linked to peptic ulcers. The worldwide prevalence of H. pylori infection and continuous research and development endeavors to optimize antibiotic treatments firmly establish their pivotal role in the peptic ulcer drugs market. Physicians' preferences for antibiotic-centric regimens and their emphasis on precision substantially contribute to the sustained dominance of antibiotics in peptic ulcer treatment paradigms.
Peptic Ulcer Drugs Market by Type
Based on type, the global peptic ulcer drugs market is segmented into duodenal ulcers, esophageal ulcers, and gastric ulcers.
Several crucial factors underlie the dominance of the duodenal ulcers segment in the global market for peptic ulcer drugs. Notably, duodenal ulcers are more prevalent than gastric ulcers, leading to more patients seeking medical treatment. The strong connection between duodenal ulcers and Helicobacter pylori (H. pylori) infection further accentuates the significance of the antibiotic segment in addressing these ulcers. The distinct and often more severe symptoms associated with duodenal ulcers drive individuals to seek medical attention, resulting in a heightened rate of diagnosis and subsequent pharmacological intervention. Advances in diagnostic techniques are pivotal in precisely identifying duodenal ulcers and facilitating timely and targeted treatment. Ongoing research and clinical emphasis on duodenal ulcers and their favorable response to pharmaceutical interventions solidify their dominance in the drug market. Global healthcare practices, adherence to standard guidelines, patient awareness initiatives, and strategic collaborations with healthcare professionals bolster the enduring prevalence of duodenal ulcers.
Peptic Ulcer Drugs Market by End User
Based on end user, the global peptic ulcer drugs market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
The dominance of the hospital pharmacies segment in the global peptic ulcer drugs market is driven by various key factors. Hospital pharmacies are pivotal in providing specialized medications for peptic ulcer treatment, offering a comprehensive range of pharmaceutical options. Inpatient treatment, often necessitated by severe peptic ulcer cases, positions hospital pharmacies as primary dispensers of these medications. Additionally, the role of hospital pharmacies in emergency care situations ensures immediate access to peptic ulcer drugs during critical moments. The convenience of obtaining these medications within the same healthcare facility that offers comprehensive medical services reinforces the dominance of hospital pharmacies. Collaborative efforts with healthcare professionals, specialized staffing, and integration with electronic health records enhance the efficiency of peptic ulcer drug management within hospital pharmacies. Furthermore, the availability of injectable medications and post-surgical care support solidifies their dominance. The strict adherence to regulatory standards ensures the quality and safety of medications dispensed by hospital pharmacies, further strengthening their position in the global peptic ulcer drugs market.
Peptic Ulcer Drugs Market by Region
Based on the region, the peptic ulcer drugs market is segmented into North America, Europe, Asia Pacific, Latin America, & the Middle East & Africa.
North America leads the global peptic ulcer drugs market with the largest revenue share. It is also expected to maintain its dominance throughout the forecast period. This market's expansion may be ascribed to several elements, including the high frequency of peptic ulcers, a large geriatric population in the region, and the sophisticated healthcare infrastructure. North America's peptic ulcer drugs market revenue is growing due to rapid expansion in R&D activities, technological progress, and high healthcare spending. The market revenue is also expected to rise due to the approval of innovative products and drugs and a large base of market participants. Furthermore, Europe is the second-largest market participant due to its developed healthcare infrastructure and high healthcare spending.
Similarly, a huge geriatric population base, a rapidly evolving healthcare infrastructure, and the rapid adoption of novel technology are all expected to contribute to the Asia Pacific market's rapid revenue growth. The revenue growth in this region is also attributed to increasing medical tourism and higher healthcare expenditure for improved medical facilities in this region.
Strategic Developments Peptic Ulcer Drugs Market
Peptic Ulcer Drugs Market Competitive Landscape
The competitive landscape in the peptic ulcer drugs market is becoming increasingly dynamic and diverse. The key players contend for dominance through innovative formulations, strategic partnerships, and geographic expansions. Factors include product efficacy, regulatory compliance, and market penetration strategies. These companies strive to gain a competitive edge by offering advanced designs, improved surgical techniques, and enhanced patient outcomes.
Some of the prominent companies having the largest revenue share in the global peptic ulcer drugs market are,
Peptic ulcers are open sores that develop on the stomach's inner lining, upper small intestine (duodenum), or esophagus. These ulcers result from the erosion of the protective lining of these digestive organs, exposing the underlying tissues to stomach acids.
Pfizer Inc., Abbott Laboratories, and Takeda Pharmaceutical Company Limited are prominent global market players.
The global peptic ulcer drugs market is expected to register a revenue CAGR of 2.59% from 2024 to 2032.
North America accounted for most of the global peptic ulcer drugs market, with most of the market.
Some hurdles that peptic ulcer drug market players experience include the availability of alternative therapies and safety concerns & side effects of the drugs.
*Insights on financial performance are subject to the availability of information in the public domain